



11FW

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:  
Commissioner for Patents, P.O. Box 1450  
Alexandria, VA 22313-1450 on August 6, 2004.

*Frank C. Eisenschenk*

Frank C. Eisenschenk, Ph.D., Patent Attorney

REQUEST FOR  
CORRECTED FILING  
RECEIPT  
Patent Application  
Examining Group 1615  
Docket No. GIR-105CXC1  
Serial No. 10/765,664  
Confirmation No. 9812

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Art Unit : 1615  
Applicant : Girsh  
Serial No. : 10/765,664  
Conf. No. : 9812  
Filed : January 26, 2004  
For : Composition with Anti-Inflammatory, Protein Synthesizing, Enzyme  
Deficiency Activating Genetic Therapy and Anti-Cancer Activity and  
Methods of Use

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

REQUEST FOR CORRECTED FILING RECEIPT

Sir:

Accompanying this Request is a Transmittal Letter submitting a response to a Notice to File Missing Parts.

Applicant respectfully requests a corrected Filing Receipt to correct a typographical error in the title, which should be, "Composition with Anti-Inflammatory, Protein Synthesizing, Enzyme Deficiency Activating Genetic Therapy and Anti-Cancer Activity and Methods of Use". A copy of page one of the subject application as filed is enclosed showing the correct title.

Applicant also respectfully requests that the corrected Filing Receipt accurately reflect the residence address of the Applicant and the corrected Domestic and Foreign Priority Data as found in the attached Submission of Application Data Sheet.

A redlined copy of the Filing Receipt as received from the U.S. Patent and Trademark Office is also enclosed.

No fees are believed due in connection with this request. However, should fees be found to be due in respect thereof, the Assistant Commissioner for Patents is hereby authorized to charge such fee or fees to counsel's Deposit Account No. 19-0065.

If any further information or documentation is required in order to accede to this request for a corrected Filing Receipt, the Office is respectfully requested to contact the undersigned by telephone at (352) 375-8100.

Respectfully submitted,



Frank C. Eisenschenk, Ph.D.

Patent Attorney

Registration No. 45,332

Phone No.: 352-375-8100

Address: 2421 N.W. 41st Street, Suite A-1  
Gainesville, FL 32606-6669

FCE/ss

Attachments: Redlined copy of Filing Receipt

Copy of Page 1 of Application As-Filed




## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22303-1450  
www.uspto.gov

APPL. NO.	FILING OR 371 (i) DATE	ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/765,664	01/26/2004	1615	385	GIR-105CXC1		8	1

CONFIRMATION NO. 9812

23557  
SALIWANCHIK LLOYD & SALIWANCHIK  
A PROFESSIONAL ASSOCIATION  
2421 N.W. 41ST STREET  
SUITE A-1  
GAINESVILLE, FL 326066669



## FILING RECEIPT



\*CC000000012522020\*

Date Mailed: 05/06/2004

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

## Applicant(s)

Leonard S. Girsh, Residence Not Provided, Palm Beach, FL

## Domestic Priority data as claimed by applicant

This application is a CIP of 10/752,298 01/05/2004  
which claims benefit of 60/437,939 01/03/2003

This application 10/765,664  
claims benefit of 60/442,278 01/24/2003  
and said 10/752,298 01/05/2004  
claims benefit of 60/447,779 02/13/2003  
and claims benefit of 60/448,003 02/18/2003  
and claims benefit of 60/448,497 02/19/2003

~~This application 10/765,664~~  
~~is a CIP of 10/269,613 10/11/2002~~  
~~which claims benefit of 60/356,890 02/22/2002~~  
~~and claims benefit of 60/350,119 11/09/2001~~  
~~and is a CIP of 09/611,857 07/07/2000 ABN~~  
~~and is a CIP of 09/701,588 02/09/2001~~

This application 10/765,664  
is a CIP of 09/639,859 08/16/2000  
which claims benefit of 60/149,338 08/17/1999

COPY

## Foreign Applications

~~UNITED STATES OF AMERICA PCT/US94/08795 06/02/1994~~

If Required, Foreign Filing License Granted: 05/04/2004

Projected Publication Date: Request for Non-Publication Acknowledged

Non-Publication Request: Yes

\*\*\*\*\*WARNING\*\*\*\*\*

Applicant has requested non-publication, certifying that the invention disclosed in this application has not been and will not be the subject of an application filed in another country, or under a multilateral agreement, that requires publication at eighteen months after filing; and has also claimed the benefit of an application filed in another country or under a multilateral agreement. Because the non-publication request and corresponding certification appears to be inconsistent with the priority claim, applicant is reminded that he/she has an obligation to promptly notify the Office and rescind the non-publication request if the invention disclosed in this application is the subject of an application filed in another country, or under a multilateral agreement, that requires eighteen-month publication.

\*\*\*\*\*WARNING\*\*\*\*\*

Early Publication Request: No

\*\* SMALL ENTITY \*\*

Title

Composition with anti-inflammatory, protein synthesizing, enzyme deficiency activating genetic therapy and ~~anti~~ cancer activity and methods of use

anti-

Preliminary Class

424

---

**LICENSE FOR FOREIGN FILING UNDER**  
**Title 35, United States Code, Section 184**  
**Title 37, Code of Federal Regulations, 5.11 & 5.15**

**GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control,

Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

**NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

DESCRIPTION

COMPOSITION WITH ANTI-INFLAMMATORY, PROTEIN SYNTHESIZING, ENZYME  
5 DEFICIENCY ACTIVATING GENETIC THERAPY AND ANTI-CANCER ACTIVITY AND

METHODS OF USE

COPY

Cross-Reference to Related Applications

10 This application is a Continuation-in-Part of application 10/752,298, filed January 5, 2004, which claims the benefit of 60/437,939, filed January 3, 2003. This application also claims the benefit of applications 60/442,278, filed January 24, 2003; 60/447,779, filed February 13, 2003; 60/448,003, filed February 18, 2003; and 60/448,497, filed February 19, 2003. This application is also a Continuation-in-Part of application 10/269,613, filed October 11, 2002,  
15 which claims the benefit of applications 60/358,890, filed February 22, 2002; 60/350,119, filed November 9, 2001; and said 10/269,613 is also a Continuation-in-Part of 09/611,857, filed July 7, 2000 and also a Continuation-in-Part of application 09/781,586, filed February 9, 2001. This application is also a Continuation-in-Part of 09/781,586, filed February 9, 2001. This application is also a Continuation-in-Part of application 09/639,859, filed August 16, 2000, which claims the  
20 benefit of application 60/149,338, filed August 17, 1999. These applications are all hereby incorporated by reference in their entireties, including all figures, formulae, references and tables.

Background of Invention

25

In prior art, the treatment of disease centers around the position to "kill" as if we are trying to kill an infectious agent. This is exemplified by the discovery that platinum kills bacteria. Many of the leading cancer products of prior art are derivatives of platinum (or similar toxic products derive from the periodic table) such as but not limited to cis-platinum and carbo  
30 platinum.